A Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

About this Study

The purpose of the Phase II part of this study is to find out what effects, good and/or bad, one of the following treatments has on participants and their cancer:  (Standard treatment) radiation therapy and cisplatin; (Experimental treatment) radiation therapy and docetaxel; or (Experimental treatment) radiation therapy, docetaxel, and cetuximab. The Phase III part of the study will compare the effects, good or bad, of the standard treatment (radiation and cisplatin) to one of the experimental arms (to be determined after completion of the Phase II part of the study) to find out which works best.

Sponsor Protocol ID:RTOG 1216
IRB Number:2014-0215
Actively Enrolling
Phase 2
May 29, 2019
Eligibility Criteria
18 years old
Both Male and Female

Inclusion CriteriaNone

Exclusion CriteriaPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute
University Hospital
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Madhava Kanakamedala
How to participate in our Clinical Trials